IS7219A - Lyfjablanda sem inniheldur (R) -bíkalútamíð - Google Patents

Lyfjablanda sem inniheldur (R) -bíkalútamíð

Info

Publication number
IS7219A
IS7219A IS7219A IS7219A IS7219A IS 7219 A IS7219 A IS 7219A IS 7219 A IS7219 A IS 7219A IS 7219 A IS7219 A IS 7219A IS 7219 A IS7219 A IS 7219A
Authority
IS
Iceland
Prior art keywords
bicalutamide
pharmaceutical composition
composition containing
pharmaceutical
composition
Prior art date
Application number
IS7219A
Other languages
English (en)
Inventor
Kay Cahill Julie
Frances Bateman Nicola
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited
Publication of IS7219A publication Critical patent/IS7219A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS7219A 2001-10-15 2004-04-14 Lyfjablanda sem inniheldur (R) -bíkalútamíð IS7219A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103424A SE0103424D0 (sv) 2001-10-15 2001-10-15 Pharmaceutical formulation
PCT/GB2002/004621 WO2003032950A1 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r) -bicalutamide

Publications (1)

Publication Number Publication Date
IS7219A true IS7219A (is) 2004-04-14

Family

ID=20285650

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7219A IS7219A (is) 2001-10-15 2004-04-14 Lyfjablanda sem inniheldur (R) -bíkalútamíð

Country Status (19)

Country Link
US (1) US20060058381A1 (is)
EP (1) EP1439823A1 (is)
JP (1) JP3639587B2 (is)
KR (1) KR20050035163A (is)
CN (1) CN1571658A (is)
AR (1) AR036877A1 (is)
BR (1) BR0213248A (is)
CA (1) CA2462219A1 (is)
CO (1) CO5580755A2 (is)
HU (1) HUP0401369A3 (is)
IL (1) IL161306A0 (is)
IS (1) IS7219A (is)
MX (1) MXPA04003520A (is)
NO (1) NO20041485L (is)
PL (1) PL368226A1 (is)
RU (1) RU2004115023A (is)
SE (1) SE0103424D0 (is)
WO (1) WO2003032950A1 (is)
ZA (1) ZA200402729B (is)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK10722003A3 (sk) * 2001-02-27 2004-02-03 Astrazeneca Ab Farmaceutická formulácia obsahujúca bicalutamid v pevnej disperzii s enterickým polymérom a jej použitie
DK3366283T3 (da) 2004-01-20 2021-11-22 Novartis Ag Direkte sammenpresningsformulering og fremgangsmåde
WO2006090129A2 (en) * 2005-02-23 2006-08-31 Astrazeneca Ab Bicalutamide for delivering increasing steady state plasma levels
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
AU2010210422A1 (en) 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
CN101987086B (zh) * 2009-08-03 2012-07-18 北京化工大学 一种超细比卡鲁胺口服片剂及其制备方法
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ，インク． 前立腺癌を処置するための新規な組成物及び方法
EP4450130A3 (en) 2012-09-11 2025-01-08 Medivation Prostate Therapeutics LLC Formulations of enzalutamide
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
RS66323B1 (sr) * 2014-12-05 2025-01-31 Aragon Pharmaceuticals Inc Sastavi protiv raka
MX381829B (es) 2014-12-05 2025-03-13 Aragon Pharmaceuticals Inc Composiciones anticancerígenas.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629237A (en) * 1968-09-12 1971-12-21 Shinetsu Chemical Co Compositions useful as enteric coatings and method for preparing acid phthalates of cellulose ethers for them
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
EP0580860B2 (en) * 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
EP0748220A4 (en) * 1994-01-21 1997-09-10 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
SK10722003A3 (sk) * 2001-02-27 2004-02-03 Astrazeneca Ab Farmaceutická formulácia obsahujúca bicalutamid v pevnej disperzii s enterickým polymérom a jej použitie
WO2002080902A1 (en) * 2001-04-02 2002-10-17 Astrazeneca Ab Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp

Also Published As

Publication number Publication date
WO2003032950A1 (en) 2003-04-24
JP2004521963A (ja) 2004-07-22
HUP0401369A2 (hu) 2004-11-29
AR036877A1 (es) 2004-10-13
MXPA04003520A (es) 2004-07-23
IL161306A0 (en) 2004-09-27
ZA200402729B (en) 2005-01-13
JP3639587B2 (ja) 2005-04-20
SE0103424D0 (sv) 2001-10-15
PL368226A1 (en) 2005-03-21
NO20041485L (no) 2004-04-13
US20060058381A1 (en) 2006-03-16
HUP0401369A3 (en) 2006-05-29
CO5580755A2 (es) 2005-11-30
KR20050035163A (ko) 2005-04-15
EP1439823A1 (en) 2004-07-28
CA2462219A1 (en) 2003-04-24
BR0213248A (pt) 2004-09-28
RU2004115023A (ru) 2005-04-10
CN1571658A (zh) 2005-01-26

Similar Documents

Publication Publication Date Title
EP1450824A4 (en) PHARMACEUTICAL COMPOSITION
FI20011478A0 (fi) Farmaseuttinen koostumus
IS2893B (is) Lyfjasamsetning sem inniheldur lantanefnasambönd
GB0111597D0 (en) Pharmaceutical compositions
AU2003276549A8 (en) Pharmaceutical compositions containing a biguanide-glitazone combination
HUP0303163A3 (en) Tramadol-based pharmaceutical composition
GB0117057D0 (en) Pharmaceutical composition
EE200300589A (et) Ravimkoostised
GB0101227D0 (en) Pharmaceutical compounds
GB0129117D0 (en) Pharmaceutical composition
GB0101225D0 (en) Pharmaceutical compounds
IS7219A (is) Lyfjablanda sem inniheldur (R) -bíkalútamíð
GB0116107D0 (en) Pharmaceutical composition
GB0104752D0 (en) Pharmaceutical compositions
GB0127805D0 (en) Pharmaceutical composition
PL370037A1 (en) Pharmaceutical composition
IS6857A (is) Lyfjafræðileg samsetning sem innheldur sítalópram
GB2382302B (en) Pharmaceutical compositions
EE200300378A (et) Farmatseutiline kompositsioon
AU2002342940A8 (en) New pharmaceutical compounds
EP1413314A4 (en) MEDICAL COMPOSITIONS
GB0125061D0 (en) Pharmaceutical composition
HU0103049D0 (en) Pharmaceutical composition
GB0126732D0 (en) Pharmaceutical compositions
IL161956A0 (en) Pharmaceutical compositions containing 5-bisoprolol